{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:18Z","timestamp":1792782798277,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cFonds voor Innovatie en Klinisch Onderzoek\u201d from Ghent University hospital and the \u2018Special Research Fund\u2019 from Ghent University","id":[{"id":"https:\/\/ror.org\/00xmkp704","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"DOI":"10.1007\/s00423-026-04121-3","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:27:15Z","timestamp":1782898035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal assessment of health-related quality of life in patients with borderline and locally advanced pancreatic cancer undergoing neoadjuvant FOLFIRINOX chemotherapy: results from a prospective multicenter trial"],"prefix":"10.1007","volume":"411","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-5512","authenticated-orcid":false,"given":"Lu\u00eds Filipe Abreu","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Meertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Rashidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Waked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Geboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzane","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Gorleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Dedecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Triest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vervaecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Sierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Beyls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Berrevoet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"4121_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"4121_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10:10\u201327","journal-title":"World J Oncol"},{"key":"4121_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.21037\/jgo-2020-slapc-04","volume":"12","author":"SO Bratlie","year":"2021","unstructured":"Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E (2021) Resectable, borderline, and locally advanced pancreatic cancer\u2014the good, the bad, and the ugly candidates for surgery? J Gastrointest Oncol 12:2450\u20132460","journal-title":"J Gastrointest Oncol"},{"key":"4121_CR4","first-page":"375","volume":"70","author":"AJ Grossberg","year":"2020","unstructured":"Grossberg AJ, Chu LC, Deig CR et al (2020) Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 70:375\u2013403","journal-title":"CA Cancer J Clin"},{"key":"4121_CR5","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921","journal-title":"Cancer Res"},{"key":"4121_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851\u2013862","journal-title":"JAMA"},{"key":"4121_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379:2395\u20132406","journal-title":"N Engl J Med"},{"key":"4121_CR8","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban EP, Mangu PB, Khorana AA et al (2016) Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 34:2654\u20132667","journal-title":"J Clin Oncol"},{"key":"4121_CR9","unstructured":"Wild CP, Weiderpass E, Stewart BW (2020) Cancer research for cancer prevention World Cancer Report"},{"key":"4121_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000002489","volume":"54","author":"L Rahib","year":"2025","unstructured":"Rahib L, Coffin T, Kenner B (2025) Factors driving pancreatic cancer survival rates. Pancreas 54:e530\u2013e536","journal-title":"Pancreas"},{"key":"4121_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf120","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Rompen IF, Ali M et al (2025) Resectability stages of pancreatic cancer: nationwide reference. Br J Surg. https:\/\/doi.org\/10.1093\/bjs\/znaf120","journal-title":"Br J Surg"},{"key":"4121_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000267","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, B\u00fcschenfelde CZ, Friess H, Kleeff J (2010) Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1000267","journal-title":"PLoS Med"},{"key":"4121_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF et al (2024) Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol 21:101\u2013124","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4121_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","author":"T Conroy","year":"2011","unstructured":"Conroy T, Ychou M, Bouch\u00e9 O et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"4121_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801\u2013810","journal-title":"Lancet Oncol"},{"key":"4121_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.hpb.2017.11.002","volume":"20","author":"SM van Dijk","year":"2018","unstructured":"van Dijk SM, Heerkens HD, Tseng DSJ, Intven M, Molenaar IQ, van Santvoort HC (2018) Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. HPB 20:204\u2013215","journal-title":"HPB"},{"key":"4121_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.hpb.2021.09.003","volume":"24","author":"TM Mackay","year":"2022","unstructured":"Mackay TM, Dijksterhuis WPM, Latenstein AEJ et al (2022) The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. HPB 24:443\u2013451","journal-title":"HPB"},{"key":"4121_CR18","doi-asserted-by":"publisher","unstructured":"Cloyd JM, Hyman S, Huwig T, Monsour C, Santry H, Wills C, Tsung A Bridges JFP Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. https:\/\/doi.org\/10.1007\/s00520-020-05813-2\/Published","DOI":"10.1007\/s00520-020-05813-2\/Published"},{"key":"4121_CR19","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1200\/JCO.23.01311","volume":"42","author":"EN Dekker","year":"2024","unstructured":"Dekker EN, Van Dam JL, Janssen QP et al (2024) Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. J Clin Oncol 42:1357\u20131367","journal-title":"J Clin Oncol"},{"key":"4121_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-025-02938-1","author":"LF Abreu de Carvalho","year":"2025","unstructured":"Abreu de Carvalho LF, Gryspeerdt F, Ceelen W et al (2025) Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol. BMC Surg. https:\/\/doi.org\/10.1186\/s12893-025-02938-1","journal-title":"BMC Surg"},{"key":"4121_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C (2022) Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom 91:8\u201335","journal-title":"Psychother Psychosom"},{"key":"4121_CR22","unstructured":"National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (2022) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 28 Mar 2022"},{"key":"4121_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","volume":"35","author":"D Fitzsimmons","year":"1999","unstructured":"Fitzsimmons D, Johnson CD, George S et al (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 35:939\u201341","journal-title":"Eur J Cancer"},{"key":"4121_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u201376","journal-title":"J Natl Cancer Inst"},{"key":"4121_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103068","author":"AM Gehrels","year":"2025","unstructured":"Gehrels AM, Vissers PAJ, Sprangers MAG et al (2025) Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2024.103068","journal-title":"EClinicalMedicine"},{"key":"4121_CR26","doi-asserted-by":"crossref","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"4121_CR27","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2020","unstructured":"R Core Team (2020) R: A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria."},{"key":"4121_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152505","volume":"17","author":"I Farnes","year":"2025","unstructured":"Farnes I, Verbeke CS, Kleive D, Waage A, Tholfsen T, Hagen M, Fosby B, Line P-D, Labori KJ (2025) Surgical, histopathological, and quality of life outcomes following neoadjuvant chemotherapy and pancreatectomy for borderline resectable and locally advanced pancreatic cancer. Cancers (Basel) 17:2505","journal-title":"Cancers (Basel)"},{"key":"4121_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad137","author":"I Farnes","year":"2023","unstructured":"Farnes I, Kleive D, Verbeke CS, Aabakken L, Issa-Epe A, Smastuen MC, Fosby BV, Dueland S, Line PD, Labori KJ (2023) Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. https:\/\/doi.org\/10.1093\/bjsopen\/zrad137","journal-title":"BJS Open"},{"key":"4121_CR30","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00520-021-06648-1","volume":"30","author":"F van der Sijde","year":"2022","unstructured":"van der Sijde F, Schafthuizen L, van \u2019t Land FR, Moskie M, van Laarhoven HWM, van Dijk M, van Eijck CHJ (2022) Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Support Care Cancer 30:2407\u20132415","journal-title":"Support Care Cancer"},{"key":"4121_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.6004\/jnccn.2024.7091","volume":"23","author":"LWF Seelen","year":"2025","unstructured":"Seelen LWF, Augustinus S, Stoop TF et al (2025) Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. JNCCN J Natl Compr Cancer Netw 23:97\u2013104","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"4121_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F et al (2020) Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5:285\u2013294","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4121_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y et al (2025) PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol 43:2255\u20132264","journal-title":"J Clin Oncol"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-026-04121-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-026-04121-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:22:23Z","timestamp":1790086943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-026-04121-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s00423-026-04121-3","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol has been approved by the central Ethics Committee of Ghent University hospital (ONZ-2022-0088; B6702022000402 on 05 December 2022) after consultation with the local Ethics Committees. Written informed consent was obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"244"}}